Open Actively Recruiting

Observation Study in Patients Age 0-5 Years With LAMA2-related Congenital Muscular Dystrophy

About

Brief Summary

The goal of this observational study is to understand how young children with LAMA2-related dystrophy move and change over time. We will also learn about how this condition impacts other body systems.

Participants will undergo:

  • Neuromuscular assessments
  • Blood collections
  • Swallowing and breathing assessments
  • Questionnaires
Study Type
Observational

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
N/A
Maximum Age
5 Years

Inclusion Criteria:

  • Signed informed consent by the subject, parent(s) or legally authorized representative (LAR) and/or assent by the subject (when applicable).
  • Subject must be aged birth to less than 5.0 years of age at time of consent.
  • A confirmed diagnosis of LAMA2-RD confirmed via: a: Two pathogenic variants in the LAMA2 gene (via a CLIA-approved laboratory) or: b. muscle biopsy with absence of merosin (laminin-211) and at least one pathogenic variant in the LAMA2 gene
  • Absence of another confirmed genetic disease.
  • Willingness to maintain current exercise and/or physical therapy regimen for the duration of the clinical study.
  • Willingness to comply with the study protocol, including but not limited to, all study procedures and visits.

Exclusion Criteria:

  • Acute medical illness or hospitalization within 30 days prior to informed consent.
  • Participation in a previous trial of any investigational agent for LAMA2-RD within 1 month prior to informed consent, or use of any other investigational therapy (including off-label use of Losartan) within 30 days prior to informed consent, or participation in other clinical studies, within 30 days (or 3 half-lives, whichever is longer) prior to informed consent, which in the opinion of the PI, may potentially confound results from this study.
  • Other significant medical condition, which in the opinion of the site Principal Investigator may confound interpretation of the clinical course of LAMA2- RD.

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Share:
Study Stats
Protocol No.
24-5720
Category
Genetic and Rare Diseases
Pediatric and Prenatal Disorders
Contact
Michael Yan
Location
  • UCLA Westwood
For Providers
NCT No.
NCT06503367
For detailed technical eligibility, visit ClinicalTrials.gov.